

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

1642
P#9

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/084,825	
	Filing Date	February 25, 2002	
	First Named Inventor	Co, Man Sung	
	Group Art Unit	Unassigned	
	Examiner Name	Unassigned	
Total Number of Pages in This Submission	32	Attorney Docket Number	011823-004012US


RECEIVED
JAN 17 2003
TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (2 pgs.) attached with SB08A (1 pg.) & SB08B (3 pgs.) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1.) Return Postcard 2.) 5 Reference Copies (25 pgs.)
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm and Individual name	Townsend and Townsend and Crew LLP Rosemarie L. Celli Reg. No. 42,397	
Signature	<i>Rosemarie L. Celli</i>	
Date	January 10, 2003	

CERTIFICATE OF MAILING		
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date: 1-10-03		
Typed or printed name	Leticia Hernandez	
Signature	<i>Leticia Hernandez</i>	Date 1-10-03

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3273775 v1



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

PATENT
Attorney Docket No.: 011823-004012US

On 1-10-03

TOWNSEND and TOWNSEND and CREW LLP

By: Leticia Hernandez
Leticia Hernandez

RECEIVED
JAN 17 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Co et al.

Application No.: 10/084,825

Filed: February 25, 2002

For: INCREASING ANTIBODY
AFFINITY BY ALTERING
GLYCOSYLATION OF
IMMUNOGLOBULIN VARIABLE
REGION

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

The references cited on attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references 1-9, 11-15, 18-23, 25-37, and 39 can be found in Application No. 08/862,871, filed May 23, 1997 (Attorney Docket No. 011823-004011US). Copies of references of 10, 16-17, 24, and 38 are enclosed herewith. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC:ewm
PA 3268603 v2



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

Application Number	10/084,825
Filing Date	February 25, 2002
First Named Inventor	Co, Man Sung, et. al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	011823-004012US

RECEIVED

JAN 17 2003

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	1	6,054,297	04-25-2000	Carter et al.	
	2	5,821,337	10-13-1998	Carter et al.	
	3	5,730,982	03-24-1998	Scheinberg	
	4	5,714,350	02-03-1998	Co et al.	
	5	5,147,637	09-15-1992	Wright et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MMDDYYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	6	WO	90/07861		07-26-1990			<input type="checkbox"/>
	7	WO	92/22653		12-23-1992			<input type="checkbox"/>
	8	EP	0 239 400		09-30-1987			<input type="checkbox"/>
	9	EP	0 438 312		07-24-1991			<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
PA 3268603 v2



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB-08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known

Application Number	10/084,825
Filing Date	February 25, 2002
First Named Inventor	Co, Man Sung, et. al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	011823-004012US

RECEIVED

JAN 17 2003

TECH CENTER 1600/2900

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T ²
	10	AMIT et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 A Resolution," <i>Science</i> , 1986, 233:747-753.	
	11	ARNAOUT et al., "Leukocyte Adhesion Molecules Deficiency: Its Structural Basis, Pathophysiology And Implications For Modulating The Inflammatory Response," <i>Immunol. Rev.</i> , 1990, 114:145-180.	
	12	BURGESS, "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <i>Journal of Cell Biology</i> , 1990, 111:2129-2138.	
	13	CARTER et al., "Humanization of an Anti-p185 ^{HER2} Antibody for Human Cancer Therapy," <i>Proc. Natl. Acad. Sci. USA</i> , 1992, 89:4285-4289.	
	14	CO et al., "Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen ¹ ," <i>Journal of Immunology</i> , 1992, 148:1149-1154.	
	15	DAUGHERTY et al., "Polymerase Chain Reaction Facilitates the Cloning, CDR-grafting, and Rapid Expression of a Murine Monoclonal Antibody Directed Against the CD18 Component of Leukocyte Integrins," <i>Nucl. Acids Res.</i> , 1991, 19(9):2471-2476.	
	16	DELENTE, "Glycosylation revisited," <i>Trends in Biotechnology</i> , 1985, 3(9):218.	
	17	GROVES et al., "Production of an Ovine Monoclonal Antibody to Testosterone by an Interspecies Fusion," <i>Hybridoma</i> , 1987, 6(1): 71-76.	
	18	HARRIS, "Therapeutic Antibodies - The Coming of Age," <i>TIBTECH</i> , February 1993, 11:42-44.	
	19	HIRD et al., "Genes and Cancer," Chapter 17, 1990, 183.	
	20	JONES et al., "Replacing the Complementarity-determining Regions, In a Human Antibody with those from a Mouse," <i>Nature</i> , 1986, 321:522-525.	
	21	LAZAR et al., "Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," <i>Molec. Cell. Biol.</i> , 1988, 8(3):1247-1252.	
	22	LEATHERBARROW et al., "Effector Functions of a Monoclonal Aglycosylated Mouse IgG2a: Binding and Activation of Complement Component C1 and Interaction With Human Monocyte Fc Receptor," <i>Molec. Immunol.</i> , 1985, 22(4):407-415.	
	23	MURAOKA and SHULMAN, "Structural Requirements for IgM Assembly and Cytolytic Activity," <i>J. Immunol.</i> , 1989, 142(2):695-701.	


Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3268603 v2



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known

Application Number	10/084,825
Filing Date	February 25, 2002
First Named Inventor	Co, Man Sung, et. al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	011823-004012US

RECEIVED

JAN 17 2003

TECH CENTER 1600/2900

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T ²
	24	PAUL, "Fundamental Immunology," 1993, Chapter 8, pg. 242, Raven Press NY.	
	25	QUEEN et al., "A Humanized Antibody that Binds to the Interleukin 2 Receptor," <i>Proc. Natl. Acad. Sci. USA</i> , 1989, 86:1029-1033.	
	26	RIECHMANN et al., "Reshaping Human Antibodies for Therapy," <i>Nature</i> , 1988, 332:323-327.	
	27	SCHEINBERG et al., "Monoclonal Antibody M195: A Diagnostic Marker for Acute Myelogenous Leukemia," <i>Leukemia</i> , 1989, 3(6):440-445.	
	28	SCHEINBERG et al., "A phase I Trial of Monoclonal Antibody M195 in Acute Myelogenous Leukemia: Specific Bone Marrow Targeting and Internalization of Radionuclide," <i>J. Clin. Oncol.</i> , 1991, 9(3):478-490.	
	29	SOX, "Attachment of Carbohydrate to the Variable Region of Myeloma Immunoglobulin Light Chains," <i>Proc. Natl. Acad. Sci.</i> , 1970, 66(3):975-982.	
	30	TANIMOTO et al., "Restricted Expression of an Early Myeloid and Monocytic Cell Surface Antigen Defined by Monoclonal Antibody M195," <i>Leukemia</i> , 1989, 3(5):339-348.	
	31	TAO et al., "Studies of Aglycosylated Chimeric Mouse-Human IgG," <i>Journal of Immunology</i> , 1989, 143:8.	
	32	TAYLOR et al., "Selective Removal of a Heavy-chain Glycosylation Sites Causes Immunoglobulin A Degradation and Reduced Secretion," <i>Molec. Cell. Biol.</i> , 1988, 8(10):4197-4203.	
	33	VERHOEYEN et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <i>Science</i> , 1988, 239:1534-1536.	
	34	WALDMANN, "Monoclonal Antibodies in Diagnosis and Therapy," <i>Science</i> , 1991, 252:1657-1662.	
	35	WALLICK et al., "Glycosylation of a V _H Residue of a Monoclonal Antibody Against (put in alpha) (1→6) Dextran Increases Its Affinity For Antigen," <i>J. Exp. Med.</i> , 1988, 168:1099-1109.	
	36	WRIGHT et al., "Antibody Variable Region Glycosylation: Position Effects on Antigen Binding and Carbohydrate Structure," <i>EMBO J.</i> , 1991, 10(10):2717-2723.	


Examiner
Signature

Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3268603 v2



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/084,825		
		Filing Date	February 25, 2002		
		First Named Inventor	Co, Man Sung, et. al.		
		Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	4	of	4	Attorney Docket Number	011823-004012US

RECEIVED

JAN 17 2003

TECH CENTER 1600/2900

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	T ²
	37	WRIGHT et al., "Identification of the C3bi Receptor Of Human Monocytes and Macrophages by using Monoclonal Antibodies," <i>Proc. Natl. Acad. Sci. USA</i> , 1983, 80:5699-5703.	
	38	WRIGHT et al., "Springer Semin Immunology," 1993, 15:259-273.	
	39	ZOLLER et al., "Oligonucleotide-Directed Mutagenesis of DNA Fragments Cloned into M13 Vectors," <i>Methods in Immunology</i> , 100:469-500.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.